FOLH1 and Familial prostate cancer: Prostate-specific membrane antigen (PSMA)-targeting peptide-drug conjugates (PDCs) offer promise for the treatment of PSMA-positive prostate cancer, but their applications are limited by rapid clearance, poor pharmacokinetics, and low efficacy.